Spots Global Cancer Trial Database for A Phase 2 Trial to Evaluate the Efficacy and Safety of OCV-501 in Elderly Patients With Acute Myeloid Leukemia
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: A Phase 2 Trial to Evaluate the Efficacy and Safety of OCV-501 in Elderly Patients With Acute Myeloid Leukemia
Official Title: A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 2 Trial to Evaluate the Efficacy and Safety of OCV-501 in Elderly Patients With Acute Myeloid Leukemia
Study ID: NCT01961882
Conditions
Study Description
Brief Summary: To compare disease-free survival in patients 60 years or older with acute myeloid leukemia (AML) who are randomly assigned to receive either OCV-501 monotherapy or placebo.
Detailed Description:
Eligibility
Minimum Age: 60 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
, Chubu Region, , Japan
, Chugoku Region, , Japan
, Hokkaido Region, , Japan
, Kanto Region, , Japan
, Kinki Region, , Japan
, Kyushu Region, , Japan
, Shikoku Region, , Japan
, Tohoku Region, , Japan
, Daegu, , Korea, Republic of
, Seoul, , Korea, Republic of
, Kaoshiung, , Taiwan
, Taichung, , Taiwan
, Tainan, , Taiwan
, Taipei, , Taiwan
Contact Details
Name: Jun-ichi Hashimoto, PhD
Affiliation: Otsuka Pharmaceutical Co., Ltd.
Role: STUDY_DIRECTOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
